Fate Therapeutics, Inc. (FRA:F6T)
Germany
· Delayed Price · Currency is EUR 0.947
+0.050 (5.62%)
At close: Dec 5, 2025
Fate Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 7.14 | 13.63 | 63.53 | 96.3 | 55.85 | 31.43 | Upgrade
|
| Revenue Growth (YoY) | -46.92% | -78.55% | -34.03% | 72.44% | 77.66% | 194.33% | Upgrade
|
| Cost of Revenue | 99.54 | 118.53 | 157.19 | 320.45 | 215.52 | 125.62 | Upgrade
|
| Gross Profit | -92.41 | -104.9 | -93.65 | -224.15 | -159.67 | -94.19 | Upgrade
|
| Selling, General & Admin | 67.59 | 90.64 | 96.86 | 84.23 | 57.32 | 33.9 | Upgrade
|
| Operating Expenses | 67.59 | 90.64 | 96.86 | 84.23 | 57.32 | 33.9 | Upgrade
|
| Operating Income | -159.99 | -195.54 | -190.51 | -308.39 | -216.99 | -128.09 | Upgrade
|
| Interest & Investment Income | 12.71 | 17.29 | 17.19 | 5.84 | 1.31 | 2.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.93 | 6.73 | 7.3 | 20.32 | 3.53 | -47.7 | Upgrade
|
| EBT Excluding Unusual Items | -141.36 | -171.53 | -166.03 | -282.22 | -212.15 | -173.39 | Upgrade
|
| Asset Writedown | -14.74 | -14.74 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 5.1 | 0.5 | - | - | Upgrade
|
| Pretax Income | -156.09 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | Upgrade
|
| Net Income | -156.09 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | Upgrade
|
| Net Income to Common | -156.09 | -186.26 | -160.93 | -281.72 | -212.15 | -173.39 | Upgrade
|
| Shares Outstanding (Basic) | 118 | 114 | 98 | 97 | 95 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 118 | 114 | 98 | 97 | 95 | 82 | Upgrade
|
| Shares Change (YoY) | 8.77% | 15.52% | 1.64% | 2.19% | 15.00% | 20.82% | Upgrade
|
| EPS (Basic) | -1.32 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | Upgrade
|
| EPS (Diluted) | -1.32 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | Upgrade
|
| Free Cash Flow | -115.43 | -123.6 | -138.42 | -283.77 | -213.57 | -44.16 | Upgrade
|
| Free Cash Flow Per Share | -0.97 | -1.09 | -1.41 | -2.93 | -2.25 | -0.54 | Upgrade
|
| Gross Margin | - | - | -147.41% | -232.77% | -285.92% | -299.64% | Upgrade
|
| Operating Margin | -2241.75% | -1434.52% | -299.86% | -320.24% | -388.56% | -407.47% | Upgrade
|
| Profit Margin | -2187.11% | -1366.46% | -253.30% | -292.55% | -379.89% | -551.59% | Upgrade
|
| Free Cash Flow Margin | -1617.32% | -906.79% | -217.87% | -294.68% | -382.43% | -140.49% | Upgrade
|
| EBITDA | -145.34 | -176.58 | -172.23 | -294.63 | -211.14 | -125 | Upgrade
|
| EBITDA Margin | - | - | -271.09% | - | - | - | Upgrade
|
| D&A For EBITDA | 14.65 | 18.96 | 18.28 | 13.76 | 5.85 | 3.09 | Upgrade
|
| EBIT | -159.99 | -195.54 | -190.51 | -308.39 | -216.99 | -128.09 | Upgrade
|
| EBIT Margin | - | - | -299.86% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.